MetLife SEC Filings

MetLife, Inc. reported that one of its non-management directors acquired 1,105 shares of MetLife common stock on 01/02/2026 at a price of $80.32 per share. This was part of the standard director compensation program, under which portions of board and board chair retainers are paid in MetLife common stock rather than cash.

The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director beneficially owns 103,859 shares of MetLife common stock in direct ownership.

MetLife, Inc. reported a routine insider equity transaction involving one of its non-management directors. On 01/02/2026, the director received 639 shares of MetLife common stock as part of non-management director retainer fees, at a price of $80.32 per share. After this award, the director beneficially owned 4,931 shares of MetLife common stock held directly.

The filing notes that MetLife’s compensation arrangements pay a portion of non-management director fees in company stock, and the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. This reflects standard equity-based compensation rather than an open-market purchase or sale.

MetLife, Inc. reported that its institutional investment arm, MetLife Investment Management, has closed the acquisition of PineBridge Investments, LLC and certain related affiliates. This step makes PineBridge part of MetLife’s investment management platform as of December 30, 2025.

On the same date, MetLife also released a fact sheet showing the pro forma combined total assets under management for MetLife Investment Management and PineBridge, as if the acquisition had been completed on September 30, 2025. The news release and the pro forma combined AUM fact sheet are provided as exhibits, giving investors more detail on how the combined investment management businesses will look following the transaction.

MetLife, Inc. is providing an early look at certain 2025 results and its capital deployment plans. For the quarter ending December 31, 2025, it estimates variable investment income of approximately $385 million to $435 million (pre-tax), compared with a quarterly target of $425 million (pre-tax) based on full-year 2025 guidance of about $1.7 billion (pre-tax). For full year 2025, MetLife anticipates a 7.7% return on its private equity portfolio and plans to use an assumed 9% annual return in its 2026 outlook, contributing to an estimated $1.6 billion (pre-tax) of variable investment income in 2026.

The company expects to deploy about $4 billion of capital in 2025 to support organic growth and approximately $1 billion for merger and acquisition activity, including funding for the expected closing of its previously announced PineBridge Investments acquisition. Total common stock repurchases for 2025 are expected to be about $2.85 billion, including roughly $430 million in the fourth quarter, with a similar repurchase level anticipated in 2026. All figures are preliminary, unaudited and subject to change as year-end closing procedures are completed.

A MetLife-related account filed a notice of proposed sale of 68 shares of common stock, to be sold through Bernstein Institutional Services LLC on the NYSE. The shares have an indicated aggregate market value of $5,556.28, while the filing notes that 658,891,656 common shares are outstanding. The seller acquired these 68 shares by purchase from Deutsche Bank on June 28, 2013, with cash payment on July 3, 2013. The notice also lists several small common stock sales by various MetLife separate accounts and retirement plans over the prior three months, each showing the number of shares sold and gross proceeds. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.

A holder of common stock has filed a Rule 144 notice to sell 359 shares of the issuer’s common stock. The filing states an aggregate market value of $29,333.89 for these shares, to be sold through Bernstein Institutional Services LLC on the NYSE, with an approximate sale date of December 19, 2025. The 359 shares were originally acquired by purchase from Goldman Sachs on December 19, 2014, with cash payment made on December 24, 2014.

The notice also lists prior sales during the past three months by related accounts, including 333 shares of common stock sold on October 1, 2025 for gross proceeds of $27,282.69 and 335 shares sold on December 1, 2025 for gross proceeds of $25,563.85. By signing, the seller represents they are not aware of any undisclosed material adverse information about the issuer.

MetLife-related accounts filed a notice to sell a small block of the issuer's common stock under SEC Rule 144. The filing covers a proposed sale of 38 shares of common stock through Bernstein Institutional Services LLC on the NYSE, with an aggregate market value of $3,104.98. The table notes that 658,891,656 shares of this class were outstanding.

The seller acquired these 38 shares in a cash purchase from Bank of America on 12/17/2019, with payment made on 12/19/2019. The notice also lists prior sales over the past three months by various MetLife-related accounts, including Separate Account II, Separate Account SPI, Separate Account 149, the MetLife 401k Plan Trust–Large Cap Equity Index, and the MetLife 401k Plan Russell 1000 Value, each selling modest amounts of common stock with disclosed dates and gross proceeds.

A holder of MetLife (MET) common stock filed a notice to sell 137 shares of common stock under Rule 144. The shares are to be sold through Bernstein Institutional Services LLC on or about 12/19/2025, with an indicated aggregate market value of 11,194.27. The filing notes that 658,891,656 shares of the issuer’s common stock were outstanding, providing context for the size of this planned sale.

The notice also lists multiple sales of the same issuer’s common stock over the prior three months by various MetLife-related accounts, each with its own share amount and gross proceeds. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.

MetLife-related accounts have filed a Rule 144 notice to sell a small block of MET common stock. The filing covers a proposed sale of 10 shares of common stock through Bernstein Institutional Services LLC, with an aggregate market value of 817.1, out of 658,891,656 shares outstanding, on or about 12/19/2025 on the NYSE.

The 10 shares to be sold were acquired by purchase from Citigroup Global Markets on 10/11/2021 and paid for in cash on 10/13/2021. The notice also lists prior sales over the past three months by various MetLife accounts and plan trusts, including small transactions such as 335 shares sold for 25,563.85 and 333 shares sold for 27,282.69.